Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Psychotherapy | Research

Psychological interventions during breast cancer rehabilitation: a randomized controlled trial comparing structured short-term psychotherapy versus non-specific group discussion

Authors: David Fauser, Elena Rimalis-Vogt, Johannes Mattes, Matthias Bethge

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Purpose

Psycho-oncological treatment is recommended in cancer rehabilitation as it improves fatigue, anxiety, depression, and quality of life in breast cancer patients. The aim of our study was to compare a structured short-term psychotherapy and a non-specific group discussion provided during breast cancer rehabilitation.

Methods

Breast cancer patients were randomly assigned to structured group short-term psychotherapy or a non-specific group discussion during breast cancer rehabilitation. The patients completed questionnaires at the beginning and end of rehabilitation and three months after rehabilitation. The primary outcome was anxiety. Secondary outcomes were depression, distress, fatigue and health-related quality of life domains.

Results

In total, 160 patients (80 in both groups) were recruited and included in the analysis. There was no significant difference between both groups in the primary outcome anxiety at the end of rehabilitation (difference = -0.2; 95% CI -1.2 to 0.7) and three months after rehabilitation (difference = 0.2; 95% CI -0.9 to 1.3) and in any secondary outcome. Patients in the short-term psychotherapy group with high anxiety levels at baseline reported fewer depressive symptoms at the end of rehabilitation.

Conclusions

Our study showed no difference between structured short-term psychotherapy and a non-specific group discussion. Patients with high baseline anxiety levels were more likely to benefit from short-term structured psychotherapy. Early identification of this subgroup and symptoms of mental illness should occur after initial treatment in breast cancer patients in order to offer a structured treatment for anxiety and depressive symptoms during rehabilitation.

Trial registration

German Clinical Trials Register (DRKS00017571; 08/07/2019).
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of Disease study. JAMA Oncol. 2019;5:1749–68.CrossRefPubMedCentral
3.
Bertuccio P, Alicandro G, Malvezzi M, Carioli G, Boffetta P, Levi F, et al. Cancer mortality in Europe in 2015 and an overview of trends since 1990. Ann Oncol. 2019;30:1356–69.CrossRefPubMed
4.
Robert Koch-Institut. Krebs in Deutschland für 2017/2018. Berlin: Robert Koch-Institut; 2021.
5.
Mehnert A, Hartung TJ, Friedrich M, Vehling S, Brähler E, Härter M, et al. One in two cancer patients is significantly distressed: prevalence and indicators of distress. Psychooncology. 2018;27:75–82.CrossRefPubMed
6.
Mehnert A, Brähler E, Faller H, Härter M, Keller M, Schulz H, et al. Four-week prevalence of mental disorders in patients with cancer across major Tumor entities. J Clin Oncol. 2014;32:3540–6.CrossRefPubMed
7.
Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74.CrossRefPubMed
8.
Faller H, Weis J, Koch U, Brähler E, Härter M, Keller M, et al. Perceived need for psychosocial support depending on emotional distress and mental comorbidity in men and women with cancer. J Psychosom Res. 2016;81:24–30.CrossRefPubMed
9.
Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ. What are the unmet supportive care needs of people with cancer? A systematic review. Support Care Cancer. 2009;17:1117–28.CrossRefPubMed
10.
Fauser D, Wienert J, Beinert T, Schmielau J, Biester I, Krüger H, et al. Work-related medical rehabilitation in patients with cancer – postrehabilitation results from a cluster-randomized multicenter trial. Cancer. 2019;125:2666–74.CrossRefPubMed
11.
Deutsche Rentenversicherung. Reha-Therapiestandards Brustkrebs für die medizinische Rehabilitation Der Rentenversicherung. Berlin: Deutsche Rentenversicherung Bund; 2016.
12.
Fors EA, Bertheussen GF, Thune I, Juvet LK, Elvsaas I-K, Oldervoll L, et al. Psychosocial interventions as part of Breast cancer rehabilitation programs? Results from a systematic review. Psychooncology. 2011;20:909–18.CrossRefPubMed
13.
Duncan M, Moschopoulou E, Herrington E, Deane J, Roylance R, Jones L, et al. Review of systematic reviews of non-pharmacological interventions to improve quality of life in cancer survivors. BMJ Open. 2017;7:e015860.CrossRefPubMedPubMedCentral
14.
Xiao F, Song X, Chen Q, Dai Y, Xu R, Qiu C, et al. Effectiveness of psychological interventions on depression in patients after Breast cancer Surgery: a meta-analysis of randomized controlled trials. Clin Breast Cancer. 2017;17:171–9.CrossRefPubMed
15.
Blanco C, Markowitz JC, Hellerstein DJ, Nezu AM, Wall M, Olfson M, et al. A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with Breast cancer. Breast Cancer Res Treat. 2019;173:353–64.CrossRefPubMed
16.
Olsson Möller U, Beck I, Rydén L, Malmström M. A comprehensive approach to rehabilitation interventions following Breast cancer treatment - a systematic review of systematic reviews. BMC Cancer. 2019;19:472.CrossRefPubMedPubMedCentral
17.
Jassim GA, Whitford DL, Hickey A, Carter B. Psychological interventions for women with non-metastatic Breast cancer. Cochrane Database Syst Rev. 2015;CD008729.
18.
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.CrossRefPubMedPubMedCentral
19.
National Comprehensive Cancer Network. Distress management. Clinical practice guidelines. J Natl Compr Canc Netw. 2003;1:344–74.CrossRef
20.
Mehnert A, Müller D, Lehmann C, Koch U. The German version of the NCCN distress thermometer. Z Klin Psychol Psychopathol Psychother. 2006;54:213–23.
21.
Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.CrossRefPubMed
22.
Zigmond AS, Snaith RP. The Hospital anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed
23.
Hinz A, Brähler E. Normative values for the hospital anxiety and depression scale (HADS) in the general German population. J Psychosom Res. 2011;71:74–8.CrossRefPubMed
24.
Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer. 1999;85:1186–96.CrossRefPubMed
25.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
26.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.CrossRefPubMed
27.
Deutsche Rentenversicherung. Klassifikation Therapeutischer Leistungen in Der Medizinischen Rehabilitation. Berlin: Deutsche Rentenversicherung Bund; 2014.
28.
Puhan MA, Frey M, Büchi S, Schünemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with Chronic Obstructive Pulmonary Disease. Health Qual Life Outcomes. 2008;6:46.CrossRefPubMedPubMedCentral
29.
Lemay KR, Tulloch HE, Pipe AL, Reed JL. Establishing the minimal clinically important difference for the hospital anxiety and Depression Scale in patients with Cardiovascular Disease. J Cardiopulm Rehabil Prev. 2019;39:E6–11.CrossRefPubMed
30.
Royston P, White IR. Multiple imputation by chained equations (MICE): implementation in Stata. J Stat Softw. 2011;45:1–20.CrossRef
31.
Vodermaier A, Millman RD. Accuracy of the hospital anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis. Support Care Cancer. 2011;19:1899–908.CrossRefPubMed
32.
Cousson-Gélie F, Bruchon-Schweitzer M, Atzeni T, Houede N. Evaluation of a psychosocial intervention on social support, perceived control, coping strategies, emotional distress, and quality of life of Breast cancer patients. Psychol Rep. 2011;108:923–42.CrossRefPubMed
33.
Setyowibowo H, Yudiana W, Hunfeld JAM, Iskandarsyah A, Passchier J, Arzomand H, et al. Psychoeducation for Breast cancer: a systematic review and meta-analysis. Breast. 2022;62:36–51.CrossRefPubMedPubMedCentral
34.
Goerling U, Foerg A, Sander S, Schramm N, Schlag PM. The impact of short-term psycho-oncological interventions on the psychological outcome of cancer patients of a surgical-oncology department – a randomised controlled study. Eur J Cancer. 2011;47:2009–14.CrossRefPubMed
35.
Weißflog G, Brähler E, Leuteritz K, Barthel Y, Kuhnt S, Wiltink J, et al. Does psychodynamic short-term psychotherapy for depressed Breast cancer patients also improve fatigue? Results from a randomized controlled trial. Breast Cancer Res Treat. 2015;152:581–8.CrossRefPubMed
36.
Beutel ME, Weißflog G, Leuteritz K, Wiltink J, Haselbacher A, Ruckes C, et al. Efficacy of short-term psychodynamic psychotherapy (STPP) with depressed Breast cancer patients: results of a randomized controlled multicenter trial. Ann Oncol. 2014;25:378–84.CrossRefPubMed
37.
Koch L, Bertram H, Eberle A, Holleczek B, Schmid-Höpfner S, Waldmann A, et al. Fear of recurrence in long-term Breast cancer survivors-still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the cancer survivorship–a multi-regional population-based study. Psychooncology. 2014;23:547–54.CrossRefPubMed
Metadata
Title
Psychological interventions during breast cancer rehabilitation: a randomized controlled trial comparing structured short-term psychotherapy versus non-specific group discussion
Authors
David Fauser
Elena Rimalis-Vogt
Johannes Mattes
Matthias Bethge
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11576-w

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses. A comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland

Research

Network Evolution Model-based prediction of tumor mutation burden from radiomic-clinical features in endometrial cancers

Research

PET-CT detection of local residual laryngeal carcinoma after definitive (chemo)radiotherapy

Research

An extensive study of potential inhibitors of extracellular vesicles release in triple-negative breast cancer

Research

Detection of pancreatic cancer with two- and three-dimensional radiomic analysis in a nationwide population-based real-world dataset

Research

Notch3 restricts metastasis of breast cancers through regulation of the JAK/STAT5A signaling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits